Related Experiment Video
Updated: Oct 11, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Risk and protective factors of non-alcoholic fatty liver disease in paediatric obesity: A nationwide nested
Resthie R Putri1, Thomas Casswall1, Emilia Hagman1
1Division of Paediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Insights
Children with severe obesity, impaired fasting glucose, and high triglycerides face higher non-alcoholic fatty liver disease (NAFLD) risks. Successful obesity treatment significantly reduces NAFLD risk, even in severe cases.
Area of Science:
- Pediatrics
- Hepatology
- Metabolic Disorders
Background:
- Non-alcoholic fatty liver disease (NAFLD) risk varies among children with obesity.
- Understanding risk factors in pediatric obesity is crucial for early intervention.
Purpose of the Study:
- To investigate the impact of obesity severity, metabolic parameters, and treatment outcomes on NAFLD risk in pediatric obesity.
- To identify key predictors of NAFLD development in children undergoing obesity treatment.
Main Methods:
- Nested case-control study using the Swedish Childhood Obesity Treatment Register (BORIS) and National Patient Register.
- Matched 76 NAFLD cases with 241 controls based on sex and age at treatment initiation.
- Analyzed the association between obesity severity (BMI SDS), metabolic factors (IFG, triglycerides), and NAFLD risk.
Main Results:
- Severe obesity (OR: 3.15), impaired fasting glucose (IFG) (OR: 5.29), and high triglycerides (OR: 2.33) significantly increased NAFLD risk.
- Weight gain during treatment correlated with higher NAFLD risk (OR: 4.67 per BMI SDS unit).
- Weight loss of ≥0.25 BMI SDS units independently reduced NAFLD risk (OR: 0.09).
Conclusions:
- Severe obesity, IFG, and high triglycerides are significant risk factors for NAFLD in pediatric obesity.
- Effective obesity treatment, particularly weight loss, can nearly eliminate NAFLD risk, irrespective of initial obesity severity or metabolic status.
Abstract:
Not all children with obesity carry a similar risk of non-alcoholic fatty liver disease (NAFLD). We investigated the effect of obesity severity, metabolic risk parameters, and obesity treatment outcome on later risk of NAFLD in paediatric obesity. We conducted a nested case-control study of children and adolescents enrolled in the Swedish Childhood Obesity Treatment Register (BORIS) (2001-2016). NAFLD was ascertained from the National Patient Register. Five controls per case were matched by sex and age at index date and at the obesity treatment initiation. Seventy-six pairs (n cases = 76, n controls = 241) were included in the analysis (29% females, mean age at obesity treatment initiation was 10.8 ± 3.07 years). Mean age of NAFLD diagnosis was 14.2 ± 3.07 years. The risk for NAFLD increased with severe obesity (odds ratio [OR]: 3.15, 95% confidence interval [CI]: 1.69-5.89), impaired fasting glucose (OR: 5.29, 95% CI: 1.40-20.06), high triglycerides (OR: 2.33, 95% CI: 1.22-4.43) and weight gain (OR: 4.67, 95% CI: 1.51-14.49 per body mass index standard deviation score [BMI SDS] unit). Relative weight loss of at least 0.25 BMI SDS units reduced NAFLD risk independently of other risk factors (OR: 0.09, 95% CI: 0.01-0.56). Severe obesity, impaired fasting glucose and high triglycerides are risk factors for future NAFLD in paediatric obesity. Successful obesity treatment almost eliminates the risk for NAFLD independently of obesity severity, IFG and high triglycerides.
Related Concept Videos
Obesity
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Metabolism

